Literature DB >> 30725316

In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid.

Valentin Al Jalali1, Robert Sauermann1, Sabine Eberl1, Markus Zeitlinger2.   

Abstract

PURPOSE: Fungal central nervous system (CNS) infections show a high mortality rate and only a few antifungal agents are available to treat these infections. We hypothesize that the different biochemical properties of human cerebrospinal fluid (CSF) compared to the standard growth medium lead to the altered activity of antifungal agents in CSF. We investigated the in vitro activity of two of these agents, i.e., amphotericin B (AmB) and voriconazole (VOR), against three different fungi in CSF in comparison to sabouraud-dextrose broth (SDB).
METHODS: CSF samples from patients who did not receive any antibiotics were collected. Time-kill curves were performed in CSF and SDB using static antibiotic concentrations of AmB and VOR against ATCC strains of Candida albicans, Candida krusei, and Cryptococcus neoformans.
RESULTS: In our experiments, both AmB and VOR showed superior activity in SDB compared to CSF. Nevertheless, AmB achieved fungicidal activity in CSF after 24 h against all test strains. Voriconazole only achieved fungistatic activity against C. albicans and C. neoformans in CSF.
CONCLUSIONS: In summary, our data demonstrate that growth of fungal pathogens but even more importantly activity of antifungal agents against Candida and Cryptococcus species can differ significantly in CSF compared to the standard growth medium. Both findings should be taken into consideration when applying PK/PD simulations to fungal infections of the CNS.

Entities:  

Keywords:  Antifungal activity; Antifungal agents; Fungal infections; Meningitis; PK/PD

Mesh:

Substances:

Year:  2019        PMID: 30725316     DOI: 10.1007/s15010-019-01275-9

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  28 in total

Review 1.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion.

Authors:  Helene Vogelsinger; Stefan Weiler; Angela Djanani; Jordan Kountchev; Rosa Bellmann-Weiler; Christian J Wiedermann; Romuald Bellmann
Journal:  J Antimicrob Chemother       Date:  2006-04-20       Impact factor: 5.790

3.  Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

Authors:  M A Pfaller; D J Diekema; R N Jones; S A Messer; R J Hollis
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman.

Authors:  Thomas Elter; Michal Sieniawski; Axel Gossmann; Claudia Wickenhauser; Ursula Schröder; Harald Seifert; Johannes Kuchta; Jürgen Burhenne; Klaus-Dieter Riedel; Gerd Fätkenheuer; Oliver A Cornely
Journal:  Int J Antimicrob Agents       Date:  2006-09       Impact factor: 5.283

5.  Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.

Authors:  A H Groll; N Giri; V Petraitis; R Petraitiene; M Candelario; J S Bacher; S C Piscitelli; T J Walsh
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

6.  Meningitis caused by Pseudallescheria boydii treated with voriconazole.

Authors:  G Poza; J Montoya; C Redondo; J Ruiz; N Vila; J L Rodriguez-Tudela; A Cerón; E Simarro
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

7.  Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management.

Authors:  P E Verweij; K Brinkman; H P Kremer; B J Kullberg; J F Meis
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

8.  In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.

Authors:  M Drago; M M Scaltrito; G Morace
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-16       Impact factor: 3.267

9.  Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.

Authors:  Irja Lutsar; Sarah Roffey; Peter Troke
Journal:  Clin Infect Dis       Date:  2003-08-07       Impact factor: 9.079

10.  Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans.

Authors:  M J Maxwell; S A Messer; R J Hollis; D J Diekema; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.